Chimenti Franco, Bolasco Adriana, Manna Fedele, Secci Daniela, Chimenti Paola, Granese Arianna, Befani Olivia, Turini Paola, Cirilli Roberto, La Torre Francesco, Alcaro Stefano, Ortuso Francesco, Langer Thierry
Dipartimento di Studi di Chimica e Tecnologia delle Sostanze Biologicamente Attive, Università degli Studi di Roma La Sapienza, Piazzale Aldo Moro 5, 00185 Rome, Italy.
Curr Med Chem. 2006;13(12):1411-28. doi: 10.2174/092986706776872907.
The present report provides a extended study of the chemistry, the inhibitory activity against monoamino oxidases (MAO), and molecular modeling including the 3D-QSAR hypothesis of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives. Four series of about eighty novel pyrazoline derivatives were prepared and investigated for their ability to inhibit the activity of the A and B isoforms of MAO selectively. Most of the new synthesized compounds proved more reversible, potent, and selective inhibitors of MAO-A than of MAO-B, and could be taken into account to develop the search further in this field, knowing that reversible and selective MAO-A inhibitors are used as antidepressant and antianxiety drug. The 30 most active compounds show inhibitory activity on MAO-A in the 8.6 x 10(-8) - 9.0 x 10(-9)M range. Moreover, it should be pointed out that for most of them a high IC(50) > or = 10(-9)M value is associated with a high A-selectivity (Selectivity Index MAO-B/MAO-A in the 10,000-16,250 range). Furthermore, due to the presence of a chiral centre at the C5 position of the pyrazole moiety, we performed the semi-preparative chromatographic enantioseparation of the most potent, selective, and chiral compounds. The separated enantiomers were then submitted to in vitro biological evaluation, and from the results of these experiments it has been possible to point out a difference in inhibiting the two isoforms selectively between the racemic mixture and the single enantiomers. The molecular modeling work was carried out combining the Glide docking approach with CoMFA with the aim to rationalize the structure-activity relationships of each pyrazoline inhibitor toward MAO-A and MAO-B isoforms and to derive a suitable selectivity model.
本报告对1,3,5-三取代-4,5-二氢-(1H)-吡唑衍生物的化学性质、对单胺氧化酶(MAO)的抑制活性以及包括3D-QSAR假设在内的分子建模进行了深入研究。制备了约八十种新型吡唑啉衍生物的四个系列,并研究了它们选择性抑制MAO A和B同工型活性的能力。事实证明,大多数新合成的化合物是比MAO-B更具可逆性、强效性和选择性的MAO-A抑制剂,鉴于可逆性和选择性MAO-A抑制剂被用作抗抑郁和抗焦虑药物,因此可以考虑在该领域进一步开展研究。30种活性最高的化合物对MAO-A的抑制活性在8.6×10(-8)-9.0×10(-9)M范围内。此外,应该指出的是,对于它们中的大多数而言,高IC(50)≥10(-9)M值与高A选择性相关(MAO-B/MAO-A选择性指数在10,000-16,250范围内)。此外,由于吡唑部分的C5位置存在手性中心,我们对最有效、选择性和手性的化合物进行了半制备色谱对映体分离。然后将分离出的对映体进行体外生物学评估,从这些实验结果中可以指出外消旋混合物和单一对映体在选择性抑制两种同工型方面的差异。结合Glide对接方法和CoMFA开展了分子建模工作,目的是阐明每种吡唑啉抑制剂对MAO-A和MAO-B同工型的构效关系,并推导合适的选择性模型。